Page last updated: 2024-09-04

desmethylcarvedilol and Diabetes Mellitus, Type 2

desmethylcarvedilol has been researched along with Diabetes Mellitus, Type 2 in 1 studies

*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coelho, EB; Della Pasqua, O; Lanchote, VL; Nardotto, GHB1

Other Studies

1 other study(ies) available for desmethylcarvedilol and Diabetes Mellitus, Type 2

ArticleYear
Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109S

    Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Carbazoles; Carvedilol; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2D6; Diabetes Mellitus, Type 2; Female; Glyburide; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Propanolamines; Stereoisomerism

2017